Literature DB >> 27573216

Incidence of Respiratory Disease During the First Two Years of Life in Children with Hemodynamically Significant Congenital Heart Disease in Italy: A Retrospective Study.

Giacomo Pongiglione1, Alessandro Possidoni2, Umberto di Luzio Paparatti2, Anna Maria Costanzo3, Giuliana Gualberti2, Marco Bonvicini4, Alessandro Rimini5, Gabriella Agnoletti6, Maria Pia Calabrò7, Marco Pozzi8, Roberto Tumbarello9, Patrizia Salice10, Patrizio Fiorini11, Maria Giovanna Russo12, Ornella Milanesi13.   

Abstract

Children affected by hemodynamically significant congenital heart disease (HSCHD) experience severe respiratory complications that can increase the frequency of hospitalizations. The aim of the SINERGY study was to describe the incidence of respiratory diseases and to collect information on active and passive immunoprophylaxis in the first 2 years of life. In this retrospective, multicenter, and epidemiologic study, children with HSCHD were enrolled across 11 Italian sites. Children born between December 31, 2007, and December 31, 2012, were observed during their first 2 years of life. Data were collected through hospital database searches and parent interviews. Four hundred twenty children were enrolled: 51.7 % were female, 79.5 % were born full-term (≥37 weeks), and 77.6 % weighed >2500 g at birth. The most frequent heart defects were ventricular septal defect (23.1 %) and coarctation of the aorta (14.3 %). The incidence of respiratory diseases was 63.1 %. Frequent respiratory diseases not requiring hospitalization were upper respiratory tract infections (76.4 %), acute bronchitis (43.3 %), and influenza (22.1 %), while those requiring hospitalization were bronchitis and bronchiolitis (8.3 % each one). While active immunoprophylaxis was applied with wide compliance (diphtheria/pertussis/tetanus, 99.5 %; Haemophilus influenzae type b, 72.5 %; pneumococcus, 79.9 %; meningococcus, 77.4 %), only 54 % of children received respiratory syncytial virus (RSV) passive prophylaxis (palivizumab). Of the 35 hospitalizations due to bronchiolitis, 27 (77.1 %) did not receive prophylaxis against RSV, compared with 8 (22.9 %) who received prophylaxis (P < 0.0001). Children with HSCHD are at major risk of respiratory diseases. Passive immunoprophylaxis can help to prevent hospitalizations for bronchiolitis.

Entities:  

Keywords:  Heart disease; Palivizumab; Respiratory infections; Respiratory syncytial virus

Mesh:

Substances:

Year:  2016        PMID: 27573216     DOI: 10.1007/s00246-016-1473-9

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  32 in total

1.  Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.

Authors:  Peta M A Alexander; Lucas Eastaugh; Jenny Royle; Andrew J Daley; Lara S Shekerdemian; Daniel J Penny
Journal:  J Paediatr Child Health       Date:  2012-05       Impact factor: 1.954

Review 2.  Acute lower respiratory tract infections in nonhospitalized children.

Authors:  F W Denny; W A Clyde
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

Review 3.  Selected populations at increased risk from respiratory syncytial virus infection.

Authors:  H Cody Meissner
Journal:  Pediatr Infect Dis J       Date:  2003-02       Impact factor: 2.129

4.  Mortality in infants with cardiovascular malformations.

Authors:  Christopher Wren; Claire A Irving; Josephine Amanda Griffiths; John J O'Sullivan; Milind P Chaudhari; Simon R Haynes; Jon H Smith; J R Leslie Hamilton; Asif Hasan
Journal:  Eur J Pediatr       Date:  2011-07-12       Impact factor: 3.183

5.  Hospitalization due to respiratory syncytial virus infection in patients under 2 years of age with hemodynamically significant congenital heart disease.

Authors:  Silvia Andres; Gabriela Bauer; Susana Rodríguez; Luis Novali; Diego Micheli; Diana Fariña
Journal:  J Pediatr (Rio J)       Date:  2012-05       Impact factor: 2.197

6.  Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children.

Authors:  Karl G Nicholson; Teresa McNally; Michael Silverman; Paul Simons; Joanne D Stockton; Maria C Zambon
Journal:  Vaccine       Date:  2005-02-25       Impact factor: 3.641

7.  Influenza in children. Relationship to other respiratory agents.

Authors:  W P Glezen; A Paredes; L H Taber
Journal:  JAMA       Date:  1980-04-04       Impact factor: 56.272

8.  Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.

Authors:  Elin Granbom; Eva Fernlund; Jan Sunnegårdh; Bo Lundell; Estelle Naumburg
Journal:  Acta Paediatr       Date:  2014-07-02       Impact factor: 2.299

9.  Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005.

Authors:  Mark D Reller; Matthew J Strickland; Tiffany Riehle-Colarusso; William T Mahle; Adolfo Correa
Journal:  J Pediatr       Date:  2008-07-26       Impact factor: 4.406

10.  Lung infection--a public health priority.

Authors:  Joseph P Mizgerd
Journal:  PLoS Med       Date:  2006-01-17       Impact factor: 11.069

View more
  2 in total

Review 1.  Time to Say Goodbye to Bronchiolitis, Viral Wheeze, Reactive Airways Disease, Wheeze Bronchitis and All That.

Authors:  Konstantinos Douros; Mark L Everard
Journal:  Front Pediatr       Date:  2020-05-05       Impact factor: 3.418

2.  Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil.

Authors:  Roseane Porfírio de Souza; Andre Luis Ribeiro Ribeiro; Sílvio Augusto Fernandes de Menezes; Luiz Fernando Almeida Machado
Journal:  BMC Pediatr       Date:  2019-08-28       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.